AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04889066
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab (initially developed as MEDI4736) is a human monoclonal antibody of the immunoglobulin (Ig) G1 kappa subclass that inhibits binding of PD-L1 (B7-H1, CD274) to PD-1 (CD279) and CD80 (B7-1). MEDI4736 is composed of 2 identical heavy chains and 2 identical light chains, with an overall molecular weight of approximately 149 kDa. MEDI4736 contains a triple mutation in the constant domain of the Ig G1 heavy chain that reduces binding to complement protein C1q and the fragment crystallizable gamma receptors involved in triggering effector function.
Trial: NCT06006624
Drug: Exparel 30 mL
RxNorm normalized name: Exparel
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mL Liposomal bupivacaine (Exparel) evenly distributed and administered in adductor canal block
Trial: NCT06006624
Drug: 0.5% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 cc's of 0.5% bupivacaine evenly distributed and administered in adductor canal
Trial: NCT06006624
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg preservative free Dexamethasone evenly distributed and administered in adductor canal
Trial: NCT06006624
Drug: iPACK block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: iPACK (Infiltration between the Popliteal artery and Capsule of the Knee) block
Trial: NCT05270798
Drug: triiodothyronine
RxNorm normalized name: Triiodothyronine
DrugBank: Liothyronine (DB00279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in septic shock who meet the diagnostic criteria for euthyroid sick syndrome will be divided into two groups; patients with low T3 levels and patients with low T3 and T4 levels. Both of these groups will be further randomly divided into patients receiving T3 hormone and patients receiving placebo.
Trial: NCT05462639
Drug: Elranatamab (PF-06863135)
RxNorm normalized name: elranatamab
DrugBank: Elranatamab (DB15395)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCMA-CD3 bispecific antibody
Trial: NCT04878692
Drug: Application of Onco-Rash cream
RxNorm normalized name: Rash Relief Antibacterial
DrugBank: Bacitracin (DB00626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The cream Onco-Rash will be administered topically. The patient will be asked to apply the cream twice a day in the morning and evening for 6 weeks to clean, dry skin on selected target areas of the body, namely: the face, the front of the neck, the front of the chest, the back of the neck and the back of the chest. The product penetrates by gentle massage.
Trial: NCT04878692
Drug: Application of Onco-Neutre cream
RxNorm normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The cream Onco-Neutre will be administered topically. The patient will be asked to apply the cream twice a day in the morning and evening for 6 weeks to clean, dry skin on selected target areas of the body, namely: the face, the front of the neck, the front of the chest, the back of the neck and the back of the chest. The product penetrates by gentle massage.
Trial: NCT04564755
Drug: abrocitinib
RxNorm normalized name: Abrocitinib
DrugBank: Abrocitinib (DB14973)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive abrocitinib 100 mg or 200 mg orally once a day as directed by the investigator's clinical judgement
Trial: NCT05579769
Drug: Ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Day +40 Dosage and Route of Administration-Ruxolitinib tablets should be administered orally BID, approximately every 12 hours, continuously, Oral
Trial: NCT05579769
Drug: Mesna
RxNorm normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Days -3 and -2 Dosage and Route of Administration-Mesna is dosed based on the cyclophosphamide dose and generally administered in fractionated doses at approximately 20% of the total cyclophosphamide dose, Intravenous.
Trial: NCT05579769
Drug: Anti-thymocyte globulin (ATG)
RxNorm normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Days -3, -2 and -1 Dosage and Route of Administration-(7 mg/kg total dose); intravenous.
Trial: NCT05579769
Drug: Cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day -1 Dosage and Route of Administration-3 mg/kg; dose will be adjusted to maintain a steady concentration between 250-350 ng/mL or trough concentration between 175-250 ng/mL when transitioned to intermittent dosing.
Trial: NCT05579769
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Days -4, -3 and -2 Dosage and Route of Administration-50 mg/m2 daily for 3 consecutive days (150 mg/m2 total dose) intravenous
Trial: NCT05579769
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Days -4, -3 and -2 Dosage and Route of Administration-3.2 mg/kg/day; intravenous.
Trial: NCT05579769
Drug: Thiotepa
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Days -6 and -5 Dosage and Route of Administration-(10 mg/kg total dose); intravenous
Trial: NCT05577637
Drug: 0.03% tacrolimus twice daily was applied on group A patients with uvb phototherapy thrice daily
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.03% tacrolimus twice daily was applied on group A patients with uvb phototherapy thrice daily
Trial: NCT05349383
Drug: Antibody-Drug Conjugate
RxNorm normalized name: antibody-drug conjugate DP303c
DrugBank: DP-303c (DB17212)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compared the case reporting of sepsis-related toxicities among ADC and other common cancer drug therapies.~ADC:including Gemtuzumab Ozogamicin, Trastuzumab Emtansine, Inotuzumab Ozogamicin, Enfortumab vedotin, Trastuzumab deruxtecan, Sacituzumab govitecan, Brentuximab Vedotin, Moxetumomab pasudotox, Polatuzumab Vedotin, Belantamab Mafodotin, loncastuximab tesirine and Tisotumab vedotin.
Trial: NCT05349383
Drug: Antineoplastic and immunomodulating agents other than Antibody-Drug Conjugate
RxNorm normalized name: conjugated estrogens and bazedoxifene
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: We would like to include other common cancer drug therapies such as chemotherapy, targeted therapy, immunotherapy and so on as a comparator group.
Trial: NCT00017758
Drug: Atorvastatin calcium
RxNorm normalized name: Atorvastatin Calcium
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00017758
Drug: Nelfinavir mesylate
RxNorm normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00017758
Drug: Efavirenz
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04847557
Drug: Tirzepatide
RxNorm normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT05796479
Drug: Amlitelimab DP1
RxNorm normalized name: Amlitelimab
DrugBank: Amlitelimab (DB18835)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection solution 1~Subcutaneous
Trial: NCT05796479
Drug: Amlitelimab DP2
RxNorm normalized name: Amlitelimab
DrugBank: Amlitelimab (DB18835)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection solution 2~Subcutaneous
Trial: NCT04917770
Drug: Sintilimab in combination with Multimodality Radiotherapy
RxNorm normalized name: miconazole
DrugBank: Sintilimab (DB15765)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will be treated with sintilimab in combination with multimodality radiotherapy
Trial: NCT05533567
Drug: Remimazolam
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The experimental group was sedated with remimazolam.
Trial: NCT05533567
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The control group was sedated with propofol.
Trial: NCT05973747
Drug: Calcium Gluconate
RxNorm normalized name: Calcium Gluconate
DrugBank: Calcium gluconate (DB11126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infused intravenously over 10 minutes upon umbilical cord clamping. First 10 assigned patients received 2 grams per protocol. Subsequent 13 patients received 1.5 grams, dose recalibrated per protocol.
Trial: NCT05973747
Drug: Calcium chloride
RxNorm normalized name: Calcium Chloride
DrugBank: Calcium chloride (DB01164)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5 grams of calcium chloride, infused intravenously over 10 minutes upon umbilical cord clamping
Trial: NCT06287307
Drug: Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY]
RxNorm normalized name: Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY]
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The semaglutide will be used in the allocated group in addition to our lifestyle program for the duration of 68 weeks in total.
Trial: NCT04545515
Drug: IVA
RxNorm normalized name: Viva
DrugBank: Adenosine (DB00640)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet for oral administration.
Trial: NCT04515329
Drug: Cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eye drops taken twice daily.
Trial: NCT04515329
Drug: Artificial tear
RxNorm normalized name: Artificial Tears
DrugBank: Propylene glycol (DB01839)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preservative-free artificial tear drops 4 times a day.
Trial: NCT05660447
Drug: Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA]
RxNorm normalized name: Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA]
DrugBank: Netarsudil (DB13931)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: One drop of rho-kinase (ROCK) inhibitor in the vitrectomized eye, once daily in the evening starting on postoperative day 1 after RRD repair surgery, till post-operative day 56
Trial: NCT05660447
Drug: Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud
RxNorm normalized name: GLYCERIN 0.2%/HYPROMELLOSE 0.2%/PEG 1%/SOLN,OPH,UD
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients enrolled in the control group will receive a placebo (one drop of artificial tears) once daily in the evening starting on postoperative day 1 after RRD repair surgery, till post-operative day 56
Trial: NCT04797806
Drug: Anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib 12 mg once a day from day 1 to 14 of a 21-day cycle.
Trial: NCT04797806
Drug: Icotinib
RxNorm normalized name: icotinib
DrugBank: Icotinib (DB11737)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Icotinib：125 mg/tablet，three times a day，fasting or serving with food. It should be continued until disease progression or intolerable toxicity or patients withdraw of consent.
Trial: NCT04798716
Drug: MSC-exosomes delivered intravenously every other day on an escalating dose (8:4:8)
RxNorm normalized name: Aldex AN
DrugBank: Doxylamine (DB00366)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Escalating dose 8 X 10\^9, 4 X 10\^9, 8 X 10\^9 mL
Trial: NCT04798716
Drug: MSC-exosomes delivered intravenously every other day (8:8:8)
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosed 8 X 10\^9, 8 X 10\^9, 8 X 10\^9 mL
Trial: NCT00000102
Drug: Nifedipine
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04940845
Drug: HS-20090-2
RxNorm normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneously injection of HS-20090-2 (60mg/1mL) once on the first day
Trial: NCT04940845
Drug: Prolia
RxNorm normalized name: Prolia
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subcutaneously injection of Prolia® (60mg/1mL) once on the first day
Trial: NCT05553392
Drug: Aquaphor
RxNorm normalized name: Aquaphor
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aquaphor is a brand of over-the-counter (OTC) skin care ointments manufactured by Beiersdorf Inc.~Aquaphor contains 41 percent petrolatum (or petroleum jelly), the active ingredient, temporarily protects minor cuts, scrapes, and burns; protects and helps relieve chapped or cracked skin and lips; helps protect from the drying effects of wind and cold weather.
Trial: NCT05669872
Drug: RBC
RxNorm normalized name: rBCG
DrugBank: VPM1002 (DB15801)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pack RBC transfusion
Trial: NCT02636686
Drug: Drisapersen
RxNorm normalized name: drisapersen
DrugBank: Drisapersen (DB13688)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive 6 mg/kg of drisapersen by subcutaneous injection once weekly. If subjects have experienced an intolerable injection site reaction(s), in consultation with the investigator, the subject may be allowed intermittent injections (8 weeks on/4 weeks off) or weekly intravenous infusions of 3 or 6 mg/kg
Trial: NCT05228483
Drug: Mometasone furoate (MMF) 0.1% ointment
DrugBank: Mometasone (DB00764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% Mometasone furoate ointment is a potent steroid and has been proven to result as efficacious and well tolerated as clobetasol propionate which represent the recomended first-line treatment of vulvar lichen sclerosus.
Trial: NCT06343077
Drug: Poly-ICLC intramuscular (IM) injection
RxNorm normalized name: poly ICLC
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg IM (week 1), followed by paired 1.5 mg IM weekly from weeks 3-through10, and at weeks 14, 18, 22, 26, 30, 34, 38, 42 and 46 with a 4-week rest period between IM injections.
Trial: NCT06343077
Drug: Poly-ICLC, Intertumoral (IT) injection
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg IT once (week 2)
Trial: NCT06008925
Drug: Nivolumab Injection
RxNorm normalized name: nivolumab Injection
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered once at 3 mg/kg intravenously on Days 8 and 22 of each cycle.
Trial: NCT04672005
Drug: Folfirinox alternating with Gemcitabine-nab-Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: modified Folfirinox every 2 weeks and biweekly Gemcitabine plus Nab-Paclitaxel
Trial: NCT05800054
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60-75 mg/m2, d1, at least 2 cycles in parallel with radiotherapy
Trial: NCT05800054
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cisplatin 25mg/m2 d1-3, 21-28d/cycle. at least 2 cycles in parallel with radiotherapy
Trial: NCT04568837
Drug: Prednisone 20 Mg
RxNorm normalized name: prednisone 20 MG
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg of Prednisone or 1 mL of 4 mg/mL Dexamethasone Sodium Phosphate will be administered each day for participants in the intervention group
Trial: NCT05233358
Drug: Regorafenib
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib is administered for 28 days per treatment cycle, with oral regorafenib on days 1-21, 80-160 mg once daily. The dose is adjusted according to adverse reactions, with a minimum of 80 mg.
Trial: NCT05233358
Drug: Immune Checkpoint Inhibitors
RxNorm normalized name: Anti-tim3 checkpoint inhibitor mbg453
DrugBank: Sabatolimab (DB16322)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optional immune checkpoint inhibitors include Camrelizumab, Sintilimab, Nivolumab, Pembrolizumab, and Toripalimab. Treatment is based on the immune checkpoint inhibitor before the patients are randomized into the group, and it is not recommended to replace the immune checkpoint inhibitor. The dosage is 200 mg, intravenous infusion, D1, once every 21 days (Q3W). Dosing interruption or dose reduction may be necessary based on individual safety and tolerability considerations; dosing with immune checkpoint inhibitors should not be suspended for more than 4 weeks.
Trial: NCT04886167
Drug: AbobotulinumtoxinA
RxNorm normalized name: abobotulinumtoxinA
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Injection of platysmal bands.
Trial: NCT05628740
Drug: 3 mg NOC-110 (via DPI)
RxNorm normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will be randomized to receive single doses of 3 mg NOC-110 (via DPI) in a crossover fashion according to a prespecified randomization schedule
Trial: NCT05628740
Drug: 6 mg NOC-110 (via DPI)
RxNorm normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will be randomized to receive single doses of 6 mg NOC-110 via DPI in a parallel fashion according to a prespecified randomization schedule
Trial: NCT04982029
Drug: Cannabidiol 100 MG/ML [Epidiolex]
RxNorm normalized name: cannabidiol 100 MG/ML [Epidiolex]
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 600mg
Trial: NCT06207682
Drug: Avacopan
RxNorm normalized name: Avacopan
DrugBank: Avacopan (DB15011)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Orally via capsules
Trial: NCT04772248
Drug: Tofacitinib
RxNorm normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: First eligible prescription for treating rheumatoid arthritis (RA)
Trial: NCT04969198
Drug: Combination nicotine replacement therapy (Nicotine patch + nicotine mini-lozenge)
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine patch and mini-lozenge dosing will be based off the 2008 Public Health Services (PHS) Clinical Practice Guideline and package insert with adjustments to account for the delayed start 1-week post-TQD. All participants will receive 2mg mini-lozenge due to the superior palatability of the 2mg lozenges. Participants are encouraged to use at least 5 mini-lozenges per day for the full 8 weeks. Participants who report any smoking or nicotine use (e.g., even a cigarette puff, e-cigarette use) in the 3 days before C-NRT distribution will receive 4 weeks of 14mg and 4 weeks of 7mg nicotine patches. Participants who report complete abstinence from smoking and nicotine in the 3 days before C-NRT distribution will receive 8 weeks of 7mg nicotine patches.
Trial: NCT05287256
Drug: Oral Delta-8-THC Cannabis
RxNorm normalized name: .DELTA.1-THC
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delta-8-THC cannabis will be orally self-administered by study participants
Trial: NCT05287256
Drug: Oral Delta-9-THC Cannabis
RxNorm normalized name: delta-9-THC
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delta-9-THC cannabis will be orally self-administered by study participants
Trial: NCT05287256
Drug: Vaporized Delta-8-THC Cannabis
RxNorm normalized name: .DELTA.1-THC
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delta-8-THC cannabis will be self-administered by study participants using a vaporizer
Trial: NCT05287256
Drug: Vaporized Delta-9-THC Cannabis
RxNorm normalized name: delta-9-THC
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delta-9-THC cannabis will be self-administered by study participants using a vaporizer
Trial: NCT05071898
Drug: Semaglutide Pen Injector [Ozempic]
RxNorm normalized name: semaglutide Pen Injector [Ozempic]
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive subcutaneously injected semaglutide (0.25 mg/wk) for 4 weeks followed by semaglutide (0.5 mg/wk) for an additional two weeks.
Trial: NCT05669092
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3mg/Kg iv d1q2w
Trial: NCT05155969
Drug: Esketamine
RxNorm normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: esketamine (0.3 mg/kg in 100 ml normal saline) is intravenously infused 40 minutes before anesthesia induction
Trial: NCT04921930
Drug: Artesunate Oral Product
RxNorm normalized name: artesunate Oral Product
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dose escalation intake of artesunate
Trial: NCT06382987
Drug: Deucravacitinib
RxNorm normalized name: Deucravacitinib
DrugBank: Deucravacitinib (DB16650)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: According to the product label
Trial: NCT06382987
Drug: Apremilast
RxNorm normalized name: Apremilast
DrugBank: Apremilast (DB05676)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: According to the product label
Trial: NCT05353192
Drug: Recombinant human growth hormone
RxNorm normalized name: Recombinant human growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant human growth hormone (15IU/5mg/3ml/bottle)，0.05 mg/kg/d by subcutaneous injection for 52 weeks
Trial: NCT06267066
Drug: Betamethasone Valerate 0.1% Cream
RxNorm normalized name: BETAMETHASONE VALERATE 0.1% CREAM
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moderate potency